← Leaderboards
Feixiong Cheng
Cleveland Clinic Lerner Com-Cwru
$12,816,805
Attributed
$26,801,471
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.9M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,801,471 · 16
By mechanism
R01$12,910,030 · 6
RF1$4,738,764 · 2
U01$4,380,268 · 2
OT2$1,699,258 · 1
R56$1,205,802 · 1
R00$746,999 · 1
Top collaborators
- Lynn Bekris6 shared
- James Bruce Leverenz6 shared
- Li Gan5 shared
- Fei Wang5 shared
- Justin D. Lathia4 shared
- Andrew A Pieper4 shared
- Borna Bonakdarpour3 shared
- Margaret E Flanagan3 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Eain A Murphy$7,074,184
- Jessica Kirkland Caldwell$4,654,032
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposUnited StatesCellsS DiseasePathogenesisMolecularDrug TargetingMedicineGenesGenomic DataNetwork-BasedMultiple OmicsPharmaceutical PreparationsBrainComplexInnovationSystems BiologyGenomicsGenome-WideProteinsAffectDrug DiscoveryAmericanGenetic
Grant awards (35)
HF-ETIOLOGY: Heart Failure Endotypes from Ethical, Multi-Modal AI driven and Molecular/Phenotypic Data Integration Enabled Discovery$1,699,258
OT2 · FY2025 · OD
A Multimodal, Multiscale and Multistage Systems Biology (M3SB) Infrastructure for Precision Medicine in Alzheimerâs Disease and Longevity$802,034
R01 · FY2025 · AG · contact PI
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$783,415
R01 · FY2025 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$781,379
R01 · FY2025 · AG · contact PI
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery$780,607
U01 · FY2025 · AG · contact PI
Mapping proteomic changes of tauopathy in human neurons$717,709
R01 · FY2025 · AG
Precision Medicine Digital Twins for Alzheimerâs Target and Drug Discovery and Longevity$552,045
R33 · FY2025 · AG · contact PI
Microglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimerâs Disease$538,304
R01 · FY2025 · AG · contact PI
Deep learning based 3D network biology knowledge portal for precision oncology$413,509
U01 · FY2025 · CA
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$809,747
R01 · FY2024 · AG · contact PI
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery$796,538
U01 · FY2024 · AG · contact PI
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$796,355
R01 · FY2024 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for AlzheimerÂs Disease$591,820
R01 · FY2024 · AG · contact PI
Microglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimerâs Disease$560,929
R01 · FY2024 · AG · contact PI
Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing$2,394,473
RF1 · FY2023 · AG · contact PI
Dark GPCR signaling underlying the Microbiome-Gut-Brain Axis for Alzheimer's Disease and Related Dementia$2,344,291
RF1 · FY2023 · NS · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$817,408
R01 · FY2023 · AG · contact PI
Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches$811,605
R01 · FY2023 · AG · contact PI
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery$796,538
U01 · FY2023 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for AlzheimerÂs Disease$721,981
R01 · FY2023 · AG · contact PI
Microglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimerâs Disease$558,166
R01 · FY2023 · AG · contact PI
Precision Medicine Digital Twins for Alzheimerâs Target and Drug Discovery and Longevity$482,520
R21 · FY2023 · AG · contact PI
TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for AlzheimerÂs Disease$831,528
R01 · FY2022 · AG · contact PI
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery$796,538
U01 · FY2022 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for AlzheimerÂs Disease$771,366
R01 · FY2022 · AG · contact PI
Multimodal single-cell genomic and epigenomic analyses elucidate Alzheimerâs sexual dimorphism in human immune systems aging$1,205,802
R56 · FY2021 · AG · contact PI
Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery$796,538
U01 · FY2021 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for AlzheimerÂs Disease$663,720
R01 · FY2021 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of In Silico Drug Repurposing for Alzheimer's Disease$322,000
R01 · FY2021 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for AlzheimerÂs Disease$634,650
R01 · FY2020 · AG · contact PI
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimer's Disease$395,914
R01 · FY2020 · AG · contact PI
An individualized network medicine infrastructure for precision cardio-oncology$248,999
R00 · FY2020 · HL · contact PI
An individualized network medicine infrastructure for precision cardio-oncology$249,000
R00 · FY2019 · HL · contact PI
An individualized network medicine infrastructure for precision cardio-oncology$249,000
R00 · FY2018 · HL · contact PI
An individualized network medicine infrastructure for precision cardio-oncology$85,785
K99 · FY2017 · HL · contact PI